Protein_Kinase

Size: px
Start display at page:

Download "Protein_Kinase"

Transcription

1 Protein Kinase 355 個 (2012/4/1 現在 ) 遺伝子シンボル説明 FXC_PID 価格 FHC_PID 価格 AAK1 AP2 associated kinase 1 FXC ,000 FHC ,000 AATK apoptosis-associated tyrosine kinase FXC ,000 FHC04004M 60,000 ABL1 c-abl oncogene 1, receptor tyrosine kinase FXC ,000 FHC ,000 ACTR2 ARP2 actin-related protein 2 homolog (yeast) FXC ,000 FHC ,000 ACVR1 Activin receptor type-1 Precursor (EC )(Activin receptor type I)(ACTR-I)(Serine/threonine-protein kinase receptor R1)(SKR1)(Activin receptor-like kinase 2)(ALK- FXC ,000 FHC ,000 2)(TGF-B superfamily receptor type I)(TSR-I) ACVR1B activin A receptor, type IB FXC ,000 FHC ,000 ACVR1C activin A receptor, type IC FXC09109M 50,000 FHC ,000 ACVRL1 activin A receptor type II-like 1, transcript variant 1 FXC28135M 50,000 FHC ,000 ADRBK1 adrenergic, beta, receptor kinase 1 FXC09648M 50,000 FHC ,000 ADRBK2 adrenergic, beta, receptor kinase 2 FXC27231M 50,000 FHC ,000 AKT1 v-akt murine thymoma viral oncogene homolog 1 FXC ,000 FHC ,000 AKT2 v-akt murine thymoma viral oncogene homolog 2 FXC ,000 FHC ,000 AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) FXC ,000 FHC ,000 ALK anaplastic lymphoma receptor tyrosine kinase FXC ,000 FHC ,000 ARAF A-Raf proto-oncogene serine/threonine-protein kinase (EC )(A-raf-1)(Proto-oncogene Pks) FXC ,000 FHC ,000 AURKA aurora kinase A FXC ,000 FHC ,000 AURKC aurora kinase C FXC ,000 FHC ,000 AXL AXL receptor tyrosine kinase FXC ,000 FHC ,000 BLK Tyrosine-protein kinase BLK (EC )(B lymphocyte kinase)(p55-blk) FXC ,000 FHC ,000 BMPR1A bone morphogenetic protein receptor, type IA FXC ,000 FHC ,000 BMPR1B Bone morphogenetic protein receptor type-1b Precursor (EC )(CDw293 antigen) FXC ,000 FHC ,000 BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) FXC ,000 FHC ,000 BMX BMX non-receptor tyrosine kinase FXC ,000 FHC ,000 BRAF B-Raf proto-oncogene serine/threonine-protein kinase (EC )(p94)(v-Raf murine sarcoma viral oncogene homolog FXC ,000 FHC ,000 BRSK2 BR serine/threonine kinase 2 FXC29626M 50,000 FHC ,000 BTK Tyrosine-protein kinase BTK (EC )(Bruton tyrosine kinase)(agammaglobulinaemia tyrosine kinase)(atk)(b-cell FXC05404M 50,000 FHC ,000 progenitor kinase)(bpk) CAMK1 calcium/calmodulin-dependent protein kinase I FXC ,000 FHC ,000 CAMK1D calcium/calmodulin-dependent protein kinase ID FXC ,000 FHC ,000 CAMK2A calcium/calmodulin-dependent protein kinase II alpha FXC ,000 FHC ,000 CAMK2B calcium/calmodulin-dependent protein kinase II beta FXC ,000 FHC ,000 CAMK2D calcium/calmodulin-dependent protein kinase II delta FXC ,000 FHC ,000 CAMK2G calcium/calmodulin-dependent protein kinase II gamma FXC10307M 50,000 FHC ,000 CAMK4 calcium/calmodulin-dependent protein kinase IV FXC ,000 FHC ,000 CAMKK1 calcium/calmodulin-dependent protein kinase kinase 1, alpha FXC10271M 50,000 FHC ,000 CAMKK2 calcium/calmodulin-dependent protein kinase kinase 2, beta FXC09184M 50,000 FHC ,000 CAMKV CaM kinase-like vesicle-associated FXC07876M 50,000 FHC ,000 CASK Peripheral plasma membrane protein CASK (hcask)(ec )(Calcium/calmodulin-dependent serine protein FXC04437M 50,000 FHC ,000 kinase)(lin-2 homolog) CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) FXC ,000 FHC ,000 CDC42BPB CDC42 binding protein kinase beta (DMPK-like) FXC ,000 FHC ,000 CDC7 cell division cycle 7 homolog (S. cerevisiae) FXC10990M 50,000 FHC ,000 CDK10 cyclin-dependent kinase 10 FXC ,000 FHC ,000 CDK11A cyclin-dependent kinase 11A FXC11114M 50,000 FHC ,000 CDK12 cyclin-dependent kinase 12 (CDK12), transcript variant 2, FXC ,000 FHC ,000 CDK12 cyclin-dependent kinase 12, transcript variant 1 FXC25993M 120,000 FHC25993M 130,000 CDK15 cyclin-dependent kinase 15 FXC11569M 50,000 FHC ,000 CDK17 cyclin-dependent kinase 17, transcript variant 1 FXC09466M 50,000 FHC ,000 CDK2 cyclin-dependent kinase 2 FXC ,000 FHC ,000 CDK20 cyclin-dependent kinase 20, transcript variant 3 FXC23550M 50,000 FHC ,000 CDK3 Cell division protein kinase 3 (EC ) FXC ,000 FHC ,000 CDK4 Cell division protein kinase 4 (EC )(Cyclindependent kinase 4)(PSK-J3) FXC ,000 FHC ,000 CDK5 cyclin-dependent kinase 5 FXC ,000 FHC ,000 CDK6 cyclin-dependent kinase 6 FXC ,000 FHC ,000 CDK7 cyclin-dependent kinase 7 FXC ,000 FHC ,000 CDK8 cyclin-dependent kinase 8 FXC24966M 50,000 FHC ,000

2 CDK9 cyclin-dependent kinase 9 FXC08042M 50,000 FHC ,000 CDKL1 cyclin-dependent kinase-like 1 (CDC2-related kinase) FXC25164M 50,000 FHC ,000 CDKL2 cyclin-dependent kinase-like 2 (CDC2-related kinase) FXC21962M 50,000 FHC ,000 CDKL3 cyclin-dependent kinase-like 3, transcript variant 1 FXC31101M 50,000 FHC ,000 CDKL4 cyclin-dependent kinase-like 4 FXC28701M 50,000 FHC ,000 CDKL5 cyclin-dependent kinase-like 5 FXC ,000 FHC ,000 CHEK1 Serine/threonine-protein kinase Chk1 (EC ) FXC ,000 FHC ,000 CHEK2 Serine/threonine-protein kinase Chk2 (EC )(Cds1) FXC ,000 FHC ,000 CHUK conserved helix-loop-helix ubiquitous kinase FXC10858M 50,000 FHC ,000 CIT citron (rho-interacting, serine/threonine kinase 21) FXC ,000 FHC ,000 CSF1R colony stimulating factor 1 receptor FXC ,000 FHC ,000 CSK Tyrosine-protein kinase CSK (EC )(C-SRC kinase)(protein-tyrosine kinase CYL) FXC ,000 FHC ,000 CSNK1A1 casein kinase 1, alpha 1 FXC ,000 FHC ,000 CSNK1A1L casein kinase 1, alpha 1-like FXC ,000 FHC ,000 CSNK1D Casein kinase I isoform delta (CKI-delta)(CKId)(EC ) FXC ,000 FHC ,000 CSNK1E casein kinase 1, epsilon FXC ,000 FHC ,000 CSNK1G1 casein kinase 1, gamma 1 FXC ,000 FHC ,000 CSNK1G2 casein kinase 1, gamma 2 FXC ,000 FHC ,000 CSNK1G3 Casein kinase I isoform gamma-3 (CKI-gamma 3)(EC FXC ,000 FHC ,000 CSNK2A1 casein kinase 2, alpha 1 polypeptide FXC08568M 50,000 FHC ,000 CSNK2A2 casein kinase 2, alpha prime polypeptide FXC ,000 FHC ,000 DAPK1 death-associated protein kinase 1 FXC ,000 FHC ,000 DAPK2 death-associated protein kinase 2 FXC25418M 50,000 FHC ,000 DAPK3 death-associated protein kinase 3 FXC26400M 50,000 FHC ,000 DCLK1 doublecortin-like kinase 1 FXC ,000 FHC ,000 DCLK2 doublecortin-like kinase 2 FXC ,000 FHC ,000 DDR1 discoidin domain receptor tyrosine kinase 1 FXC ,000 FHC ,000 DMPK dystrophia myotonica-protein kinase FXC ,000 FHC ,000 DYRK1B dual-specificity tyrosine-(y)-phosphorylation regulated kinase FXC ,000 FHC ,000 DYRK2 Dual specificity tyrosine-phosphorylation-regulated kinase 2 (EC ) FXC ,000 FHC ,000 DYRK3 dual-specificity tyrosine-(y)-phosphorylation regulated kinase FXC ,000 FHC ,000 DYRK4 dual-specificity tyrosine-(y)-phosphorylation regulated kinase FXC ,000 FHC ,000 EGFR epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian) FXC09683M 110,000 FHC09683M 120,000 EIF2AK1 Eukaryotic translation initiation factor 2-alpha kinase 1 FXC ,000 FHC ,000 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2, transcript variant 2 FXC20967M 50,000 FHC ,000 EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2, transcript variant 3 FXC20968M 50,000 FHC20968M 60,000 EIF2AK4 eukaryotic translation initiation factor 2 alpha kinase 4 FXC ,000 FHC ,000 EPHA2 EPH receptor A2 FXC09635M 50,000 FHC ,000 EPHA3 EPH receptor A3 FXC ,000 FHC ,000 EPHA5 EPH receptor A5 FXC ,000 FHC ,000 EPHA7 EPH receptor A7 FXC ,000 FHC ,000 EPHA8 EPH receptor A8 FXC ,000 FHC ,000 EPHB1 EPH receptor B1 FXC31004M 50,000 FHC ,000 EPHB2 EPH receptor B2 FXC ,000 FHC ,000 EPHB3 EPH receptor B3 FXC ,000 FHC ,000 EPHB4 EPH receptor B4 FXC23022M 50,000 FHC ,000 EPHB6 EPH receptor B6 FXC ,000 FHC ,000 ERBB2 Receptor tyrosine-protein kinase erbb-2 Precursor (EC )(p185erbB2)(C-erbB-2)(NEU protooncogene)(tyrosine FXC ,000 FHC11836M 60,000 kinase-type cell surface receptor ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian), transcript variant 1 FXC28149M 50,000 FHC ,000 ERBB4 Homo sapiens v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) (ERBB4), transcript variant JM-a/CVT-1 FXC21305M 110,000 FHC21305M 120,000 ERBB4 Homo sapiens v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) (ERBB4), transcript variant JM-a/CVT-2 FXC21306M 110,000 FHC21306M 120,000 ERN1 endoplasmic reticulum to nucleus signaling 1 FXC ,000 FHC ,000 FER Proto-oncogene tyrosine-protein kinase FER (c-fer)(ec )(p94-FER)(Tyrosine kinase 3) FXC03985M 50,000 FHC ,000 FES feline sarcoma oncogene FXC11018M 50,000 FHC ,000 FGFR1 Basic fibroblast growth factor receptor 1 Precursor (FGFR- 1)(bFGF-R)(EC )(Fms-like tyrosine kinase 2)(cfgr)(CD331 FXC ,000 FHC ,000 antigen) FGFR2 fibroblast growth factor receptor 2 FXC24041M 110,000 FHC24041M 120,000 FGFR3 fibroblast growth factor receptor 3 FXC ,000 FHC ,000 FGFR3 fibroblast growth factor receptor 3 FXC ,000 FHC10468M 60,000

3 FGFR4 fibroblast growth factor receptor 4 FXC09979M 50,000 FHC ,000 FGR Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene FXC20165M 50,000 FHC ,000 FLT1 fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor) FXC ,000 FHC ,000 FLT3 fms-related tyrosine kinase 3 FXC28201M 90,000 FHC28201M 100,000 FRK fyn-related kinase FXC ,000 FHC ,000 FYN FYN oncogene related to SRC, FGR, YES FXC ,000 FHC ,000 GRK1 G protein-coupled receptor kinase 1 FXC11140M 50,000 FHC ,000 GRK5 G protein-coupled receptor kinase 5 FXC24037M 50,000 FHC ,000 GRK6 G protein-coupled receptor kinase 6 (EC )(G proteincoupled receptor kinase GRK6) FXC ,000 FHC ,000 GRK7 G protein-coupled receptor kinase 7 Precursor (EC )(G protein-coupled receptor kinase GRK7) FXC ,000 FHC ,000 GSK3A glycogen synthase kinase 3 alpha FXC09232M 50,000 FHC ,000 GSK3B glycogen synthase kinase 3 beta FXC ,000 FHC ,000 GUCY2D guanylate cyclase 2D, membrane (retina-specific) FXC ,000 FHC ,000 HCK hemopoietic cell kinase FXC28810M 50,000 FHC ,000 HIPK2 homeodomain interacting protein kinase 2 FXC11119M 50,000 FHC ,000 HIPK3 homeodomain interacting protein kinase 3 FXC ,000 FHC ,000 ICK intestinal cell (MAK-like) kinase FXC ,000 FHC ,000 IGF1R insulin-like growth factor 1 receptor FXC ,000 FHC ,000 IKBKB Inhibitor of nuclear factor kappa-b kinase subunit beta (Ikappa-B-kinase beta)(ikbkb)(ikk-beta)(ikk-b)(ec )(I-kappa-B kinase 2)(IKK2)(Nuclear factor NFkappa-B FXC ,000 FHC ,000 inhibitor kinase beta)(nfkbikb) IKBKE inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon FXC ,000 FHC ,000 ILK integrin-linked kinase FXC ,000 FHC ,000 INSR insulin receptor FXC11132M 50,000 FHC ,000 IRAK1 interleukin-1 receptor-associated kinase 1 FXC ,000 FHC ,000 IRAK2 Interleukin-1 receptor-associated kinase-like 2 (IRAK-2) FXC ,000 FHC ,000 IRAK3 interleukin-1 receptor-associated kinase 3 FXC24800M 50,000 FHC ,000 IRAK4 interleukin-1 receptor-associated kinase 4 FXC08686M 50,000 FHC ,000 ITK IL2-inducible T-cell kinase FXC10993M 50,000 FHC ,000 JAK1 Tyrosine-protein kinase JAK1 (EC )(Janus kinase 1)(JAK-1) FXC ,000 FHC ,000 KALRN kalirin, RhoGEF kinase FXC ,000 FHC ,000 KDR kinase insert domain receptor (a type III receptor tyrosine FXC21921M 50,000 FHC ,000 KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene FXC ,000 FHC ,000 LATS1 LATS, large tumor suppressor, homolog 1 (Drosophila) FXC29211M 50,000 FHC ,000 LCK Proto-oncogene tyrosine-protein kinase LCK (EC )(Lymphocyte cell-specific protein-tyrosine FXC ,000 FHC ,000 kinase)(p56-lck)(lsk)(t cell-specific protein-tyrosine kinase) LIMK1 LIM domain kinase 1 FXC ,000 FHC ,000 LIMK2 LIM domain kinase 2 (LIMK-2)(EC ) FXC ,000 FHC ,000 LMTK2 lemur tyrosine kinase 2 FXC ,000 FHC ,000 LMTK2 Serine/threonine-protein kinase LMTK2 Precursor (EC )(Lemur tyrosine kinase 2)(Serine/threonine protein kinase KPI-2)(Kinase/phosphatase/inhibitor 2)(Apoptosisassociated FXC05532M 50,000 FHC ,000 tyrosine kinase 2)(Brain-enriched kinase)(hbrek)(cdk5/p35-regulated kinase)(cprk) LMTK3 lemur tyrosine kinase 3 FXC ,000 FHC00294M 60,000 LYN Tyrosine-protein kinase Lyn (EC ) FXC ,000 FHC ,000 MAK Serine/threonine-protein kinase MAK (EC )(Male germ cell-associated kinase) FXC ,000 FHC ,000 MAP2K1 mitogen-activated protein kinase kinase 1 FXC ,000 FHC ,000 MAP2K2 mitogen-activated protein kinase kinase 2 FXC ,000 FHC ,000 MAP2K3 mitogen-activated protein kinase kinase 3 FXC ,000 FHC ,000 MAP2K4 mitogen-activated protein kinase kinase 4 FXC25904M 50,000 FHC ,000 MAP2K5 mitogen-activated protein kinase kinase 5 FXC ,000 FHC ,000 MAP2K6 mitogen-activated protein kinase kinase 6 FXC ,000 FHC ,000 MAP2K7 mitogen-activated protein kinase kinase 7 FXC ,000 FHC ,000 MAP3K10 mitogen-activated protein kinase kinase kinase 10 FXC11092M 50,000 FHC ,000 MAP3K11 mitogen-activated protein kinase kinase kinase 11 FXC24308M 50,000 FHC ,000 MAP3K12 mitogen-activated protein kinase kinase kinase 12, transcript variant 2 FXC24753M 50,000 FHC ,000 MAP3K13 mitogen-activated protein kinase kinase kinase 13, transcript variant 1 FXC21785M 50,000 FHC ,000 MAP3K2 mitogen-activated protein kinase kinase kinase 2 FXC ,000 FHC ,000 MAP3K3 mitogen-activated protein kinase kinase kinase 3 FXC ,000 FHC ,000 MAP3K4 mitogen-activated protein kinase kinase kinase 4 FXC05920M 50,000 FHC ,000

4 MAP3K5 mitogen-activated protein kinase kinase kinase 5 FXC ,000 FHC ,000 MAP3K6 mitogen-activated protein kinase kinase kinase 6 FXC11020M 50,000 FHC ,000 MAP3K7 mitogen-activated protein kinase kinase kinase 7 FXC ,000 FHC ,000 MAP3K8 Mitogen-activated protein kinase kinase kinase 8 (EC )(COT proto-oncogene serine/threonine-protein kinase)(cancer Osaka thyroid oncogene)(c-cot)(tumor FXC ,000 FHC ,000 progression locus 2)(TPL-2) MAP4K1 mitogen-activated protein kinase kinase kinase kinase 1 FXC ,000 FHC ,000 MAP4K3 mitogen-activated protein kinase kinase kinase kinase 3 FXC ,000 FHC ,000 MAP4K4 mitogen-activated protein kinase kinase kinase kinase 4 FXC ,000 FHC ,000 MAP4K5 mitogen-activated protein kinase kinase kinase kinase 5 FXC ,000 FHC ,000 MAPK1 mitogen-activated protein kinase 1 FXC ,000 FHC ,000 MAPK10 mitogen-activated protein kinase 10 FXC ,000 FHC ,000 MAPK11 mitogen-activated protein kinase 11 FXC ,000 FHC ,000 MAPK12 Mitogen-activated protein kinase 12 (EC )(Extracellular signal-regulated kinase 6)(ERK- 6)(ERK5)(Stress-activated protein kinase 3)(Mitogenactivated FXC ,000 FHC ,000 protein kinase p38 gamma)(map kinase p38 MAPK13 mitogen-activated protein kinase 13 FXC ,000 FHC ,000 MAPK14 mitogen-activated protein kinase 14 FXC ,000 FHC ,000 MAPK15 Mitogen-activated protein kinase 15 (EC )(Extracellular signal-regulated kinase 8) FXC ,000 FHC ,000 MAPK3 mitogen-activated protein kinase 3 FXC ,000 FHC ,000 MAPK4 mitogen-activated protein kinase 4 FXC29878M 50,000 FHC ,000 MAPK6 mitogen-activated protein kinase 6 FXC ,000 FHC ,000 MAPK7 Mitogen-activated protein kinase 7 (EC )(Extracellular signal-regulated kinase 5)(ERK- FXC ,000 FHC ,000 5)(ERK4)(Big MAP kinase 1)(BMK1 kinase) MAPK8 Mitogen-activated protein kinase 8 (EC )(Stressactivated protein kinase JNK1)(c-Jun N-terminal kinase FXC ,000 FHC ,000 MAPK9 mitogen-activated protein kinase 9 FXC ,000 FHC ,000 MAPKAPK2 mitogen-activated protein kinase-activated protein kinase 2 FXC20795M 50,000 FHC ,000 MAPKAPK3 mitogen-activated protein kinase-activated protein kinase 3 FXC ,000 FHC ,000 MARK1 MAP/microtubule affinity-regulating kinase 1 FXC ,000 FHC ,000 MARK3 MAP/microtubule affinity-regulating kinase 3 (EC )(Cdc25C-associated protein kinase 1)(C- TAK1)(cTAK1)(Serine/threonine-protein kinase p78)(ser/thr FXC ,000 FHC ,000 protein kinase PAR-1)(Protein kinase STK10) MARK4 MAP/microtubule affinity-regulating kinase 4 FXC ,000 FHC ,000 MAST1 microtubule associated serine/threonine kinase 1 FXC ,000 FHC ,000 MAST3 microtubule associated serine/threonine kinase 3 FXC ,000 FHC ,000 MAST4 microtubule associated serine/threonine kinase family FXC ,000 FHC ,000 MATK megakaryocyte-associated tyrosine kinase FXC26396M 50,000 FHC ,000 MERTK c-mer proto-oncogene tyrosine kinase FXC11823M 50,000 FHC ,000 MINK1 misshapen-like kinase 1 FXC09529M 50,000 FHC ,000 MKNK1 MAP kinase-interacting serine/threonine-protein kinase 1 (EC )(MAP kinase signal-integrating kinase 1)(Mnk1) FXC ,000 FHC ,000 MKNK2 MAP kinase-interacting serine/threonine-protein kinase 2 (EC )(MAP kinase signal-integrating kinase 2)(Mnk2) FXC ,000 FHC ,000 MLKL Mixed lineage kinase domain-like protein FXC ,000 FHC ,000 MLTK Mitogen-activated protein kinase kinase kinase MLT FXC ,000 FHC ,000 MOS v-mos Moloney murine sarcoma viral oncogene homolog FXC ,000 FHC ,000 MUSK muscle, skeletal, receptor tyrosine kinase, transcript variant 1 FXC31275M 50,000 FHC ,000 MYLK myosin light chain kinase FXC ,000 FHC ,000 MYLK2 myosin light chain kinase 2 FXC ,000 FHC ,000 MYLK4 myosin light chain kinase family, member 4 FXC ,000 FHC ,000 MYT1 myelin transcription factor 1 FXC ,000 FHC ,000 NEK1 NIMA (never in mitosis gene a)-related kinase 1 FXC ,000 FHC ,000 NEK10 NIMA (never in mitosis gene a)- related kinase 10 FXC21464M 90,000 FHC21464M 100,000 NEK11 Serine/threonine-protein kinase Nek11 (EC )(Never in mitosis A-related kinase 11)(NimA-related protein kinase 11) FXC ,000 FHC ,000 NEK2 Serine/threonine-protein kinase Nek2 (EC )(NimArelated protein kinase 2)(NimA-like protein kinase 1)(HSPK FXC ,000 FHC ,000 NEK3 NIMA (never in mitosis gene a)-related kinase 3 FXC ,000 FHC ,000 NEK6 NIMA (never in mitosis gene a)-related kinase 6 FXC ,000 FHC ,000 NEK7 NIMA (never in mitosis gene a)-related kinase 7 FXC ,000 FHC ,000 NEK9 NIMA (never in mitosis gene a)- related kinase 9 FXC ,000 FHC ,000 NLK Serine/threonine protein kinase NLK FXC ,000 FHC ,000 NRBP1 Nuclear receptor-binding protein FXC ,000 FHC ,000 NRBP2 nuclear receptor binding protein 2 FXC31650M 50,000 FHC ,000 NTRK1 neurotrophic tyrosine kinase, receptor, type 1, transcript FXC20642M 50,000 FHC ,000

5 NTRK2 neurotrophic tyrosine kinase, receptor, type 2 FXC ,000 FHC ,000 NTRK2 neurotrophic tyrosine kinase, receptor, type 2 FXC12007M 80,000 FHC12007M 90,000 NTRK3 neurotrophic tyrosine kinase, receptor, type 3 FXC ,000 FHC ,000 NUAK1 NUAK family, SNF1-like kinase, 1 FXC ,000 FHC ,000 NUAK2 NUAK family, SNF1-like kinase, 2 FXC ,000 FHC ,000 OSR1 odd-skipped related 1 (Drosophila) FXC10938M 50,000 FHC ,000 PAK4 p21 protein (Cdc42/Rac)-activated kinase 4 FXC ,000 FHC ,000 PAK6 p21 protein (Cdc42/Rac)-activated kinase 6 FXC ,000 FHC ,000 PAK7 p21 protein (Cdc42/Rac)-activated kinase 7 FXC ,000 FHC ,000 PASK PAS domain containing serine/threonine kinase FXC ,000 FHC ,000 PBK PDZ binding kinase FXC ,000 FHC ,000 PDGFRB platelet-derived growth factor receptor, beta polypeptide FXC ,000 FHC ,000 PDIK1L PDLIM1 interacting kinase 1 like FXC ,000 FHC ,000 PDK1 [Pyruvate dehydrogenase [lipoamide]] kinase isozyme 1, mitochondrial Precursor (EC )(Pyruvate FXC ,000 FHC ,000 dehydrogenase kinase isoform 1) PHKG2 phosphorylase kinase, gamma 2 (testis) FXC ,000 FHC ,000 PIM1 pim-1 oncogene FXC ,000 FHC ,000 PIM2 pim-2 oncogene FXC ,000 FHC ,000 PIM3 pim-3 oncogene FXC ,000 FHC ,000 PINK1 PTEN induced putative kinase 1 FXC ,000 FHC ,000 PKN1 Serine/threonine-protein kinase N1 (EC )(Protein kinase C-like 1)(Protein-kinase C-related kinase 1)(Protein FXC ,000 FHC ,000 kinase C-like PKN)(Serine-threonine protein kinase N)(Protein PKN2 Serine/threonine-protein kinase N2 (EC )(Protein kinase C-like 2)(Protein-kinase C-related kinase 2) FXC ,000 FHC ,000 PKN3 protein kinase N3 FXC23660M 50,000 FHC ,000 PLK1 Serine/threonine-protein kinase PLK1 (EC )(Pololike kinase 1)(PLK-1)(Serine/threonine-protein kinase FXC ,000 FHC ,000 PLK2 polo-like kinase 2 (Drosophila) FXC ,000 FHC ,000 PLK4 polo-like kinase 4 FXC09597M 50,000 FHC ,000 PNCK pregnancy up-regulated non-ubiquitously expressed CaM FXC ,000 FHC ,000 PRKAA1 protein kinase, AMP-activated, alpha 1 catalytic subunit, transcript variant 1 FXC22157M 50,000 FHC ,000 PRKAA2 protein kinase, AMP-activated, alpha 2 catalytic subunit FXC20333M 50,000 FHC ,000 PRKACA protein kinase, camp-dependent, catalytic, alpha FXC ,000 FHC ,000 PRKACB protein kinase, camp-dependent, catalytic, beta FXC ,000 FHC ,000 PRKACG protein kinase, camp-dependent, catalytic, gamma FXC ,000 FHC ,000 PRKCA Protein kinase C alpha type (PKC-alpha)(PKC-A)(EC FXC ,000 FHC ,000 PRKCB Protein kinase C beta type (PKC-beta)(PKC-B)(EC ) FXC ,000 FHC ,000 PRKCD Protein kinase C delta type (EC )(nPKC-delta) FXC ,000 FHC ,000 PRKCE protein kinase C, epsilon FXC ,000 FHC ,000 PRKCG Protein kinase C gamma type (PKC-gamma)(EC ) FXC ,000 FHC ,000 PRKCH protein kinase C, eta FXC ,000 FHC ,000 PRKCI protein kinase C, iota FXC21760M 50,000 FHC ,000 PRKCQ Protein kinase C theta type (EC )(nPKC-theta) FXC ,000 FHC ,000 PRKCZ protein kinase C, zeta FXC ,000 FHC ,000 PRKG1 protein kinase, cgmp-dependent, type I FXC23849M 50,000 FHC ,000 PRKG2 protein kinase, cgmp-dependent, type II FXC ,000 FHC ,000 PRKX protein kinase, X-linked FXC27284M 50,000 FHC ,000 PRPF4B PRP4 pre-mrna processing factor 4 homolog B (yeast) FXC ,000 FHC ,000 PSKH1 protein serine kinase H1 FXC ,000 FHC ,000 PSKH2 protein serine kinase H2 FXC23327M 50,000 FHC ,000 PTK2B Protein tyrosine kinase 2 beta (EC )(Focal adhesion kinase 2)(FADK 2)(Proline-rich tyrosine kinase 2)(Cell adhesion kinase beta)(cak beta)(calcium-dependent tyrosine FXC ,000 FHC ,000 kinase)(cadtk)(related adhesion focal tyrosine PTK6 Tyrosine-protein kinase 6 (EC )(Breast tumor kinase)(tyrosine-protein kinase BRK) FXC ,000 FHC ,000 RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 FXC ,000 FHC ,000 RET ret proto-oncogene FXC ,000 FHC ,000 RIPK1 receptor (TNFRSF)-interacting serine-threonine kinase 1 FXC22422M 50,000 FHC ,000 RIPK2 Receptor-interacting serine/threonine-protein kinase 2 (EC )(RIP-like-interacting CLARP kinase)(receptorinteracting protein 2)(RIP-2)(CARD-containing interleukin-1 FXC ,000 FHC ,000 beta-converting enzyme-associated kinase)(card-containing IL-1 beta ICE-kinase) ROCK1 Rho-associated, coiled-coil containing protein kinase 1 FXC26266M 50,000 FHC ,000 ROCK2 Rho-associated, coiled-coil containing protein kinase 2 FXC ,000 FHC ,000 ROR1 receptor tyrosine kinase-like orphan receptor 1 FXC20341M 50,000 FHC ,000 ROR2 receptor tyrosine kinase-like orphan receptor 2 FXC12087M 50,000 FHC ,000

6 RPS6KA1 ribosomal protein S6 kinase, 90kDa, polypeptide 1 FXC ,000 FHC ,000 RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 FXC ,000 FHC ,000 RPS6KA3 ribosomal protein S6 kinase, 90kDa, polypeptide 3 FXC ,000 FHC ,000 RPS6KA6 Ribosomal protein S6 kinase alpha-6 (S6K-alpha 6)(EC )(90 kda ribosomal protein S6 kinase 6)(p90-RSK FXC ,000 FHC ,000 6)(Ribosomal S6 kinase 4)(RSK-4)(pp90RSK4) RPS6KB1 ribosomal protein S6 kinase, 70kDa, polypeptide 1 FXC ,000 FHC ,000 RPS6KB2 ribosomal protein S6 kinase, 70kDa, polypeptide 2 FXC ,000 FHC ,000 RYK RYK receptor-like tyrosine kinase FXC ,000 FHC ,000 SBK1 SH3-binding domain kinase 1 FXC28376M 50,000 FHC ,000 SBK2 Putative uncharacterized serine/threonine-protein kinase SgK069 (EC )(Sugen kinase 69) FXC ,000 FHC ,000 SCYL2 SCY1-like protein 2 (Coated vesicle-associated kinase of 104 FXC ,000 FHC00814M 60,000 SCYL2 SCY1-like 2 (S. cerevisiae) FXC11487M 50,000 FHC ,000 SGK2 serum/glucocorticoid regulated kinase 2 FXC ,000 FHC ,000 SGK3 serum/glucocorticoid regulated kinase family, member 3 FXC ,000 FHC ,000 SGK494 Uncharacterized serine/threonine-protein kinase SgK494(Sugen kinase 494) FXC ,000 FHC ,000 SIK1 salt-inducible kinase 1 FXC10354M 50,000 FHC ,000 SNRK SNF related kinase FXC ,000 FHC ,000 SRC Proto-oncogene tyrosine-protein kinase Src (EC )(pp60c-src)(p60-Src)(c-Src) FXC ,000 FHC ,000 SRPK1 SRSF protein kinase 1, transcript variant 1 FXC31137M 50,000 FHC ,000 SRPK2 SFRS protein kinase 2 FXC ,000 FHC ,000 SRPK3 SFRS protein kinase 3 FXC ,000 FHC ,000 STK11 Serine/threonine-protein kinase 11 (EC )(Serine/threonine-protein kinase LKB1)(Renal FXC ,000 FHC ,000 STK16 serine/threonine kinase 16, transcript variant 1 FXC29997M 50,000 FHC ,000 STK17A serine/threonine kinase 17a FXC22919M 50,000 FHC ,000 STK24 serine/threonine kinase 24 (STE20 homolog, yeast) FXC09574M 50,000 FHC ,000 STK25 serine/threonine kinase 25 (STE20 homolog, yeast) FXC ,000 FHC ,000 STK3 serine/threonine kinase 3 (STE20 homolog, yeast) FXC ,000 FHC ,000 STK32A Serine/threonine-protein kinase 32A (EC )(YANK1) FXC ,000 FHC ,000 STK32B serine/threonine kinase 32B FXC ,000 FHC ,000 STK33 Serine/threonine-protein kinase 33 (EC ) FXC ,000 FHC ,000 STK35 Serine/threonine-protein kinase 35 (EC )(CLP-36- interacting kinase)(clik1)(pdlim1-interacting kinase 1) FXC ,000 FHC ,000 STK36 serine/threonine kinase 36, fused homolog (Drosophila) FXC09188M 50,000 FHC ,000 STK38 serine/threonine kinase 38 FXC ,000 FHC ,000 STK38L serine/threonine kinase 38 like FXC ,000 FHC ,000 STK40 serine/threonine kinase 40 FXC ,000 FHC ,000 STRADB STE20-related kinase adaptor beta FXC21281M 50,000 FHC ,000 STYK1 serine/threonine/tyrosine kinase 1 FXC ,000 FHC ,000 SYK spleen tyrosine kinase FXC ,000 FHC ,000 TAOK1 TAO kinase 1 FXC ,000 FHC ,000 TAOK2 TAO kinase 2 FXC ,000 FHC ,000 TAOK3 TAO kinase 3 FXC09805M 50,000 FHC ,000 TBCK TBC1 domain containing kinase FXC08413M 50,000 FHC ,000 TBK1 TANK-binding kinase 1 FXC31490M 50,000 FHC ,000 TEC tec protein tyrosine kinase FXC11113M 50,000 FHC ,000 TEK TEK tyrosine kinase, endothelial FXC ,000 FHC ,000 TESK2 testis-specific kinase 2 FXC ,000 FHC ,000 TGFBR1 transforming growth factor, beta receptor 1 FXC ,000 FHC ,000 TGFBR2 transforming growth factor, beta receptor II (70/80kDa) FXC ,000 FHC ,000 TIE1 tyrosine kinase with immunoglobulin-like and EGF-like FXC ,000 FHC ,000 TLK1 tousled-like kinase 1 FXC ,000 FHC ,000 TLK2 tousled-like kinase 2 FXC ,000 FHC ,000 TNIK TRAF2 and NCK interacting kinase FXC ,000 FHC ,000 TNK1 tyrosine kinase, non-receptor, 1 FXC09586M 50,000 FHC ,000 TNNI3K TNNI3 interacting kinase FXC20376M 50,000 FHC ,000 TRIB1 tribbles homolog 1 (Drosophila) FXC ,000 FHC ,000 TRIB2 tribbles homolog 2 (Drosophila) FXC ,000 FHC ,000 TRIB3 tribbles homolog 3 (Drosophila) FXC ,000 FHC ,000 TRIO triple functional domain (PTPRF interacting) FXC22132M 50,000 FHC ,000 TSSK1B Testis-specific serine/threonine-protein kinase 1 FXC ,000 FHC ,000 TSSK2 testis-specific serine kinase 2 FXC ,000 FHC ,000 TSSK3 testis-specific serine kinase 3 FXC ,000 FHC ,000 TSSK4 Testis-specific serine/threonine-protein kinase 4 (TSSK- 4)(Testis-specific kinase 4)(TSK-4)(EC FXC ,000 FHC , )(Serine/threonine-protein kinase 22E) TSSK6 testis-specific serine kinase 6 FXC ,000 FHC ,000

7 TTBK2 tau tubulin kinase 2 FXC ,000 FHC ,000 TTK TTK protein kinase FXC07900M 80,000 FHC07900M 90,000 TXK TXK tyrosine kinase FXC21911M 50,000 FHC ,000 TYK2 tyrosine kinase 2 FXC10017M 50,000 FHC ,000 TYRO3 TYRO3 protein tyrosine kinase FXC ,000 FHC ,000 UHMK1 U2AF homology motif (UHM) kinase 1 FXC ,000 FHC ,000 ULK1 unc-51-like kinase 1 (C. elegans) FXC ,000 FHC ,000 ULK2 unc-51-like kinase 2 (C. elegans) FXC ,000 FHC ,000 ULK3 unc-51-like kinase 3 (C. elegans) FXC ,000 FHC ,000 VRK1 vaccinia related kinase 1 FXC ,000 FHC ,000 VRK2 vaccinia related kinase 2 FXC ,000 FHC ,000 WEE1 WEE1 homolog (S. pombe) FXC ,000 FHC ,000 WNK1 WNK lysine deficient protein kinase 1 FXC12495M 50,000 FHC ,000 WNK2 Serine/threonine-protein kinase WNK2 (EC )(Protein kinase with no lysine 2)(Protein kinase, lysine-deficient FXC ,000 FHC ,000 2)(Serologically defined colon cancer antigen 43)(Antigen NY- WNK3 WNK lysine deficient protein kinase 3 FXC11560M 50,000 FHC ,000 YES1 v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1 FXC ,000 FHC ,000 ZAP70 Tyrosine-protein kinase ZAP-70 (EC )(70 kda zetaassociated protein)(syk-related tyrosine kinase) FXC ,000 FHC ,000

BTR 6110BTR CTC CTC CTC-HER2-1 -

BTR 6110BTR CTC CTC CTC-HER2-1 - 0-1. 6110BTR 6110BTR CTC CTC CTC-HER2-1 - 0-2. 0-3. 0-4. 0-5. 0-6. 0-7. - 2 - - 3-0-8. tsurutani_j@dotd.med.kindai.ac.jp ykodera@med.kindai.ac.jp ...- 1-0-1.... - 1-0-2....- 2-0-3....- 2-0-4....- 2-0-5....-

More information

細胞周期とチェックポイント

細胞周期とチェックポイント -CDK DNA 4 G 1 S G 2 M 3 (check points) G 1 DNA G 2 /M DNA DNA DNA 2 CDK CDK cylcin-dependent kinase 34 kda, Ser/Thr [ ] (Cyclin)5060 kda [ ] 1. (Rao & Johnson, 1970 ) a) M M b) S S G 2 /M S c) M S DNA

More information

第86回日本感染症学会総会学術集会後抄録(II)

第86回日本感染症学会総会学術集会後抄録(II) χ μ μ μ μ β β μ μ μ μ β μ μ μ β β β α β β β λ Ι β μ μ β Δ Δ Δ Δ Δ μ μ α φ φ φ α γ φ φ γ φ φ γ γδ φ γδ γ φ φ φ φ φ φ φ φ φ φ φ φ φ α γ γ γ α α α α α γ γ γ γ γ γ γ α γ α γ γ μ μ κ κ α α α β α

More information

第79回_プログラム.indd

第79回_プログラム.indd Regulation of ghrelin signaling by a leptin-induced gene, negative regulatory element-binding protein, in the hypothalamic neurons. Phase I clinical trial using peptide vaccine for human vascular endothelial

More information

受賞講演要旨2012cs3

受賞講演要旨2012cs3 アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート アハ ート α β α α α α α

More information

一般演題(ポスター)

一般演題(ポスター) 6 5 13 : 00 14 : 00 A μ 13 : 00 14 : 00 A β β β 13 : 00 14 : 00 A 13 : 00 14 : 00 A 13 : 00 14 : 00 A β 13 : 00 14 : 00 A β 13 : 00 14 : 00 A 13 : 00 14 : 00 A β 13 : 00 14 : 00 A 13 : 00 14 : 00 A

More information

ito.dvi

ito.dvi 1 2 1006 214 542 160 120 160 1 1916 49 1710 55 1716 1 2 1995 1 2 3 4 2 3 1950 1973 1969 1989 1 4 3 3.1 3.1.1 1989 2 3.1.2 214 542 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

More information

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2) (1) I 44 II 45 III 47 IV 52 44 4 I (1) ( ) 1945 8 9 (10 15 ) ( 17 ) ( 3 1 ) (2) 45 II 1 (3) 511 ( 451 1 ) ( ) 365 1 2 512 1 2 365 1 2 363 2 ( ) 3 ( ) ( 451 2 ( 314 1 ) ( 339 1 4 ) 337 2 3 ) 363 (4) 46

More information

i ii i iii iv 1 3 3 10 14 17 17 18 22 23 28 29 31 36 37 39 40 43 48 59 70 75 75 77 90 95 102 107 109 110 118 125 128 130 132 134 48 43 43 51 52 61 61 64 62 124 70 58 3 10 17 29 78 82 85 102 95 109 iii

More information

ABN”Ð…J…^…“…OP01-24.indd

ABN”Ð…J…^…“…OP01-24.indd H00008086-M02 AAAS monoclonal antibody (M02), clone 5A1 ELISA, IHC, West 100 g / 52,000 H00009625-M01 AATK monoclonal antibody (M01), clone 5H5 ELISA, IHC 100 g / 52,000 H00009625-M03 AATK monoclonal antibody

More information

m «É w «Ÿ ÉÉ É É ÉÉ É É

m «É w «Ÿ ÉÉ É É ÉÉ É É É ÉÉÉÉ ÉÉ Zacc m «É w «Ÿ ÉÉ É É ÉÉ É É É É É É É É É ÉÉ É Uninephrectomy induces Progressive Glomerulosclerosis and Apoptosis in Anti Thy Glomerulonephritis VEGF Gene Expression is Correlated with Glomerular

More information

第85 回日本感染症学会総会学術集会後抄録(III)

第85 回日本感染症学会総会学術集会後抄録(III) β β α α α µ µ µ µ α α α α γ αβ α γ α α γ α γ µ µ β β β β β β β β β µ β α µ µ µ β β µ µ µ µ µ µ γ γ γ γ γ γ µ α β γ β β µ µ µ µ µ β β µ β β µ α β β µ µµ β µ µ µ µ µ µ λ µ µ β µ µ µ µ µ µ µ µ

More information

2

2 2 3 4 5 6 7 8 9 1 2 3 4 5 10 11 12 1 2 1 2 1 2 13 14 3 17 15 1 2 3 D Usefulness of Tc-99m MIBI SPECT in predicting multidrug resistance gene expression level in non-small cell lung cancer a preliminary

More information

0120

0120 文部科学省 科学研究費補助金 新学術領域研究 修飾シグナル病 第二回公開シンポジウム 修飾シグナル病 学術領域の新展開 抄録集 プログラム 2012年1月28日 土 13:00 17:30 東京大学医科学研究所 1号館1F講堂 領域代表者 井上純一郎 2 2012 1 28 13:00-13:10 13:10-15:10 1...2...4...6...8 15:30-17:20 2...10...12...14

More information

分子系統樹作成方法

分子系統樹作成方法 実 習 1: MEGA6 のダウンロードとインストール MEGA の Web サイトは http://www.megasoftware.net/( 下 図 ) 正 式 には 左 側 の[Windows]ボタンをクリックし 名 前 とメールアドレスを 入 力 して[Submit Request]をクリックすると ダウンロード 用 のアドレスがメールで 送 られる 実 習 2: 配 列 データのダウンロードとアライメント

More information

467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 B =(1+R ) B +G τ C C G τ R B C = a R +a W W ρ W =(1+R ) B +(1+R +δ ) (1 ρ) L B L δ B = λ B + μ (W C λ B )

More information

indd

indd Molecular Targeted Therapy for Lung Cancer from a Pharmaceutical Point of Viewe Naho SASAKI epidermal growth factor receptor tyrosine kinase inhibitor :EGFR-TKI vascular endothelial growth factor:vegf

More information

9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00

9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00 9 : 00 11 : 00 12 : 00 12 : 10 12 : 50 13 : 30 14 : 40 16 : 00 17 : 00 ポスターについて 1. ポスター 貼 付 用 の 展 示 ボードは 縦 180 横 90cm の 大 きさです 2. 演 題 名 発 表 者 名 所 属 を 明 記 したもの(20 70cm) をご 用 意 ください 実 際 使 用 できるスペースは 155

More information

Title 骨量規定転写因子シュニュリ3の新規標的遺伝子同定と機能解析 Author(s) 石堂, 康弘 Citation Issue Date 2014-06-27 URL http://hdl.handle.net/10232/24125 http://ir.kagoshima-u.ac.jp adult (Schnurri, Shn)3/Hivep3 Runx2 Shn/Hivep Shn3

More information

星医会51号.indb

星医会51号.indb 1 , / / / / / / / / / / / / / / / / / /,, / / / /// /// / / / / / / / // / CBT / / / / / / 2 / / / / / /. / / / / / / / / POS / / / / / / / / /,,, CBT 3 / / / / / / / / 4 5 ARDS ? 6 CT MRI PET/CT 7 8 MESS

More information

i

i 14 i ii iii iv v vi 14 13 86 13 12 28 14 16 14 15 31 (1) 13 12 28 20 (2) (3) 2 (4) (5) 14 14 50 48 3 11 11 22 14 15 10 14 20 21 20 (1) 14 (2) 14 4 (3) (4) (5) 12 12 (6) 14 15 5 6 7 8 9 10 7

More information

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...

- - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8... 取 扱 説 明 書 - - - - - - - - - - - - - - - - - - - - - - - - - -1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - -2...2...3...4...4...4...5...6...7...8...9...11 - - - - - - - - - - - - - - - - -

More information

第 1 章 書 類 の 作 成 倍 角 文 字 SGML 系 書 類 のみ 使 用 できます 文 字 修 飾 改 行 XML 系 書 類 では 文 字 修 飾 ( 半 角 / 下 線 / 上 付 / 下 付 )と 改 行 が 使 用 できます SGML 系 書 類 では 文 字 修 飾 ( 半 角

第 1 章 書 類 の 作 成 倍 角 文 字 SGML 系 書 類 のみ 使 用 できます 文 字 修 飾 改 行 XML 系 書 類 では 文 字 修 飾 ( 半 角 / 下 線 / 上 付 / 下 付 )と 改 行 が 使 用 できます SGML 系 書 類 では 文 字 修 飾 ( 半 角 1.2 HTML 文 書 の 作 成 基 準 1.2.2 手 続 書 類 で 使 用 できる 文 字 全 角 文 字 手 続 書 類 で 使 用 できる 文 字 種 類 文 字 修 飾 について 説 明 します 参 考 JIS コードについては 付 録 J JIS-X0208-1997 コード 表 をご 覧 ください XML 系 SGML 系 共 通 JIS-X0208-1997 情 報 交 換 用

More information

日本糖尿病学会誌第58巻第3号

日本糖尿病学会誌第58巻第3号 l l μ l l l l l μ l l l l μ l l l l μ l l l l l l l l l l l l l μ l l l l μ Δ l l l μ Δ μ l l l l μ l l μ l l l l l l l l μ l l l l l μ l l l l l l l l μ l μ l l l l l l l l l l l l μ l l l l β l l l μ

More information

2 アドレナリン 受 容 体 と 薬 理 作 用 受 容 体 組 織 作 用 大 部 分 の 血 管 平 滑 筋 収 縮 瞳 孔 散 大 筋 収 縮 ( 瞳 孔 散 大 ) α1 α2 立 毛 筋 ラット 肝 細 胞 心 臓 中 枢 シナプス 後 膜 血 小 板 神 経 終 末 (シナプス 前 膜

2 アドレナリン 受 容 体 と 薬 理 作 用 受 容 体 組 織 作 用 大 部 分 の 血 管 平 滑 筋 収 縮 瞳 孔 散 大 筋 収 縮 ( 瞳 孔 散 大 ) α1 α2 立 毛 筋 ラット 肝 細 胞 心 臓 中 枢 シナプス 後 膜 血 小 板 神 経 終 末 (シナプス 前 膜 Adrenergic Drugs 1 Adrenergic Synapse 交 感 神 経 終 末 に 取 り 込 まれた tyrosine は tyrosine hydroxylase により DOPA となり DOPA decarboxylase により Dopamine となる Dopamine は Dopamine-β-hydroxylase により Norepinephrine(NE)になり

More information

24.15章.微分方程式

24.15章.微分方程式 m d y dt = F m d y = mg dt V y = dy dt d y dt = d dy dt dt = dv y dt dv y dt = g dv y dt = g dt dt dv y = g dt V y ( t) = gt + C V y ( ) = V y ( ) = C = V y t ( ) = gt V y ( t) = dy dt = gt dy = g t dt

More information

第1部 一般的コメント

第1部 一般的コメント (( 2000 11 24 2003 12 31 3122 94 2332 508 26 a () () i ii iii iv (i) (ii) (i) (ii) (iii) (iv) (a) (b)(c)(d) a) / (i) (ii) (iii) (iv) 1996 7 1996 12

More information

日本糖尿病学会誌第58巻第2号

日本糖尿病学会誌第58巻第2号 β γ Δ Δ β β β l l l l μ l l μ l l l l α l l l ω l Δ l l Δ Δ l l l l l l l l l l l l l l α α α α l l l l l l l l l l l μ l l μ l μ l l μ l l μ l l l μ l l l l l l l μ l β l l μ l l l l α l l μ l l

More information

1 (1) (2)

1 (1) (2) 1 2 (1) (2) (3) 3-78 - 1 (1) (2) - 79 - i) ii) iii) (3) (4) (5) (6) - 80 - (7) (8) (9) (10) 2 (1) (2) (3) (4) i) - 81 - ii) (a) (b) 3 (1) (2) - 82 - - 83 - - 84 - - 85 - - 86 - (1) (2) (3) (4) (5) (6)

More information

- 2 -

- 2 - - 2 - - 3 - (1) (2) (3) (1) - 4 - ~ - 5 - (2) - 6 - (1) (1) - 7 - - 8 - (i) (ii) (iii) (ii) (iii) (ii) 10 - 9 - (3) - 10 - (3) - 11 - - 12 - (1) - 13 - - 14 - (2) - 15 - - 16 - (3) - 17 - - 18 - (4) -

More information

2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1

2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4 4 4 2 5 5 2 4 4 4 0 3 3 0 9 10 10 9 1 1 1 1979 6 24 3 4 4 4 4 3 4 4 2 3 4 4 6 0 0 6 2 4 4 4 3 0 0 3 3 3 4 3 2 4 3? 4 3 4 3 4 4 4 4 3 3 4 4 4 4 2 1 1 2 15 4 4 15 0 1 2 1980 8 4 4 4 4 4 3 4 2 4 4 2 4 6 0 0 6 4 2 4 1 2 2 1 4 4 4 2 3 3 3 4 3 4 4

More information

第88回日本感染症学会学術講演会後抄録(III)

第88回日本感染症学会学術講演会後抄録(III) !!!! β! !!μ μ!!μ μ!!μ! !!!! α!!! γδ Φ Φ Φ Φ! Φ Φ Φ Φ Φ! α!! ! α β α α β α α α α α α α α β α α β! β β μ!!!! !!μ !μ!μ!!μ!!!!! !!!!!!!!!! !!!!!!μ! !!μ!!!μ!!!!!! γ γ γ γ γ γ! !!!!!! β!!!! β !!!!!! β! !!!!μ!!!!!!

More information

第1章 国民年金における無年金

第1章 国民年金における無年金 1 2 3 4 ILO ILO 5 i ii 6 7 8 9 10 ( ) 3 2 ( ) 3 2 2 2 11 20 60 12 1 2 3 4 5 6 7 8 9 10 11 12 13 13 14 15 16 17 14 15 8 16 2003 1 17 18 iii 19 iv 20 21 22 23 24 25 ,,, 26 27 28 29 30 (1) (2) (3) 31 1 20

More information

EVOS FL Auto Imaging System with Onstage Incubator EVOS FL Auto Imaging System PCIncubator Incubator LED Water reservoir USB EVOS FL Auto Imaging Syst

EVOS FL Auto Imaging System with Onstage Incubator EVOS FL Auto Imaging System PCIncubator Incubator LED Water reservoir USB EVOS FL Auto Imaging Syst Live Cell Imaging EVOS FL Auto Imaging System with Onstage Incubator Invitrogen CellLight BacMam 2.0 Molecular Probes EVOS FL Auto Imaging System with Onstage Incubator EVOS FL Auto Imaging System PCIncubator

More information

330

330 330 331 332 333 334 t t P 335 t R t t i R +(P P ) P =i t P = R + P 1+i t 336 uc R=uc P 337 338 339 340 341 342 343 π π β τ τ (1+π ) (1 βτ )(1 τ ) (1+π ) (1 βτ ) (1 τ ) (1+π ) (1 τ ) (1 τ ) 344 (1 βτ )(1

More information

日本分子第4巻2号_10ポスター発表.indd

日本分子第4巻2号_10ポスター発表.indd JSMI Report 62 63 JSMI Report γ JSMI Report 64 β α 65 JSMI Report JSMI Report 66 67 JSMI Report JSMI Report 68 69 JSMI Report JSMI Report 70 71 JSMI Report JSMI Report 72 73 JSMI Report JSMI Report 74

More information

204 / CHEMISTRY & CHEMICAL INDUSTRY Vol.69-1 January 2016 047

204 / CHEMISTRY & CHEMICAL INDUSTRY Vol.69-1 January 2016 047 9 π 046 Vol.69-1 January 2016 204 / CHEMISTRY & CHEMICAL INDUSTRY Vol.69-1 January 2016 047 β γ α / α / 048 Vol.69-1 January 2016 π π π / CHEMISTRY & CHEMICAL INDUSTRY Vol.69-1 January 2016 049 β 050 Vol.69-1

More information

表1票4.qx4

表1票4.qx4 iii iv v 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 22 23 10 11 24 25 26 27 10 56 28 11 29 30 12 13 14 15 16 17 18 19 2010 2111 22 23 2412 2513 14 31 17 32 18 33 19 34 20 35 21 36 24 37 25 38 2614

More information

ÿþ

ÿþ I O 01 II O III IV 02 II O 03 II O III IV III IV 04 II O III IV III IV 05 II O III IV 06 III O 07 III O 08 III 09 O III O 10 IV O 11 IV O 12 V O 13 V O 14 V O 15 O ( - ) ( - ) 16 本 校 志 望 の 理 由 入 学 後 の

More information

ただし EMT はメタや invasion と 同 義 ではないことを 強 調 しておきたい c. Apoptosis や anoikis に 対 する 抵 抗 性 正 常 では 表 皮 細 胞 は 間 質 細 胞 との 接 着 に 失 敗 すると apoptosis(programmed cell

ただし EMT はメタや invasion と 同 義 ではないことを 強 調 しておきたい c. Apoptosis や anoikis に 対 する 抵 抗 性 正 常 では 表 皮 細 胞 は 間 質 細 胞 との 接 着 に 失 敗 すると apoptosis(programmed cell 癌 転 移 : 最 近 の 発 見 新 しい 治 療 戦 略 Metastasis: recent discoveries and novel treatment strategies The Lancet, vol369, No.9574, May 19-25, 2007, Suzanne A Eccles 他 西 伊 豆 早 朝 カンファランス 仲 田 1.Introduction 癌 転 移

More information

14-2JAMTTCNL0913F

14-2JAMTTCNL0913F JAMTTC News Letter No.14-2 Sept. 2010 http://jamttc.umin.jp Japanese Association for Molecular Target Therapy of Cancer information September, 2010 1 News 2 Japanese Association for Molecular Target Therapy

More information

provider_020524_2.PDF

provider_020524_2.PDF 1 1 1 2 2 3 (1) 3 (2) 4 (3) 6 7 7 (1) 8 (2) 21 26 27 27 27 28 31 32 32 36 1 1 2 2 (1) 3 3 4 45 (2) 6 7 5 (3) 6 7 8 (1) ii iii iv 8 * 9 10 11 9 12 10 13 14 15 11 16 17 12 13 18 19 20 (2) 14 21 22 23 24

More information

平成14年度 本態性多種化学物質過敏状態の調査研究 研究報告書

平成14年度 本態性多種化学物質過敏状態の調査研究 研究報告書 226 227 µ 228 Ω 229 230 0 ppb 2000ppb DG subthreshold (µa) 91 ± 59 86 ± 68 max stim. (µa) 755 ± 287 n=37 678 ± 300 max PS (mv) 8.7 ± 3.9 7.7 ± 4.3 n=61 CA1 subthreshold (µa) 36 ± 26 32 ± 13 max stim. (µa)

More information

肺 がんの 予 後 (5 年 生 存 率 ) I 期 II 期 III 期 IV 期 全 体 日 本 (がん 研 究 振 興 財 団 ) 日 本 ( 全 国 が んセンター 協 議 会 ) 米 国 (American Cancer Society HP 16) 71.7% 83.6% 38.3% 4

肺 がんの 予 後 (5 年 生 存 率 ) I 期 II 期 III 期 IV 期 全 体 日 本 (がん 研 究 振 興 財 団 ) 日 本 ( 全 国 が んセンター 協 議 会 ) 米 国 (American Cancer Society HP 16) 71.7% 83.6% 38.3% 4 資 料 1-2 癌 治 療 のコスト 考 察 ; 特 に 肺 癌 の 最 新 治 療 について 平 成 28 年 4 月 4 日 日 本 赤 十 字 社 医 療 センター 化 学 療 法 科 部 長 國 頭 英 夫 肺 がんの 予 後 (5 年 生 存 率 ) I 期 II 期 III 期 IV 期 全 体 日 本 (がん 研 究 振 興 財 団 ) 日 本 ( 全 国 が んセンター 協 議 会

More information

第89回日本感染症学会学術講演会後抄録(I)

第89回日本感染症学会学術講演会後抄録(I) ! ! ! β !!!!!!!!!!! !!! !!! μ! μ! !!! β! β !! β! β β μ! μ! μ! μ! β β β β β β μ! μ! μ!! β ! β ! ! β β ! !! ! !!! ! ! ! β! !!!!! !! !!!!!!!!! μ! β !!!! β β! !!!!!!!!! !! β β β β β β β β !!

More information

ATTENTION TO GOLF CLUB LAUNCHER DST DRIVER 04 05 LAUNCHER DST TOUR DRIVER LAUNCHER DST DRIVER LAUNCHER DST TOUR DRIVER LAUNCHER DST DRIVER LAUNCHER DST TOUR DRIVER 06 07 LAUNCHER DST FAIRWAY WOOD LAUNCHER

More information

Microsoft Word - 第58回日本脂質生化学会プログラムv1.doc

Microsoft Word - 第58回日本脂質生化学会プログラムv1.doc 1 2 3 4 i-bac 1 1 2 2 3 2 3 2,4 1 2 3 i-bac 1 2 1 2 1 1,3 1 2 Wake Forest School of Medicine 1,2 1 1 Lawrence L. Rudel 2 1 1 2 1 1 1 1 2 2 1 1 2 3 4 1 2 3 2 2 2 2 4 1 2 1 2 1 1 2 1 1 1 1 2 3 1 1 1 1 3

More information

「産業上利用することができる発明」の審査の運用指針(案)

「産業上利用することができる発明」の審査の運用指針(案) 1 1.... 2 1.1... 2 2.... 4 2.1... 4 3.... 6 4.... 6 1 1 29 1 29 1 1 1. 2 1 1.1 (1) (2) (3) 1 (4) 2 4 1 2 2 3 4 31 12 5 7 2.2 (5) ( a ) ( b ) 1 3 2 ( c ) (6) 2. 2.1 2.1 (1) 4 ( i ) ( ii ) ( iii ) ( iv)

More information

i ii iii iv v vi vii ( ー ー ) ( ) ( ) ( ) ( ) ー ( ) ( ) ー ー ( ) ( ) ( ) ( ) ( ) 13 202 24122783 3622316 (1) (2) (3) (4) 2483 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) 11 11 2483 13

More information

スライド 1

スライド 1 遺伝子パスウェイを用いた疾患関連遺伝子群の同定 愛知医大公衆衛生学 西山毅 ( たけし ) nishiyama@minos.ocn.ne.jp CNV とは 今までは 1 塩基単位の多型 (SNP) を用いるのが主流 巨大塩基配列数 (= コピー数 ) を通常よりも多く持つ人と, 少なく持つ人がいるので, コピー数多型 Copy Number Variation (CNV) と呼ぶ 従来の解析法 :

More information

ボールねじ

ボールねじ A A 506J A15-6 A15-8 A15-8 A15-11 A15-11 A15-14 A15-19 A15-20 A15-24 A15-24 A15-26 A15-27 A15-28 A15-30 A15-32 A15-35 A15-35 A15-38 A15-38 A15-39 A15-40 A15-43 A15-43 A15-47 A15-47 A15-47 A15-47 A15-49

More information

11713_SciSig_vol14p

11713_SciSig_vol14p Science Signaling 日 本 語 版 ダイジェスト vol.14 http://www.sciencesignaling.org/ ScienceSignaling.org Science Signaling Science Signaling Science Signaling Editorial Guide Focus Issue:TOR シグナル 伝 達 2 つの Focus Issue:

More information

Microsoft Word - ■3中表紙(2006版).doc

Microsoft Word - ■3中表紙(2006版).doc 18 Annual Report on Research Activity by Faculty of Medicine, University of the Ryukyus 2006 FACULTY OF MEDICINE UNIVERSITY OF THE RYUKYUS α αγ α β α βγ β α β α β β β γ κα κ κ βγ ε α γδ β

More information

jcvp試験問題HP.indd

jcvp試験問題HP.indd 22 18 JCVP 1 G a e 1 G 1. A. B. C. D. P450 E. SOD c G 2. A. B. C. mrna D. E. G 3. G 4. A. B. ATP C. D. E. a A. B. C. 25 nm D. 10 nm E. 4 6 nm c d G 5. G 6. G 7. A. B. SOD C. D. E α E. d a. b. c. d. e.

More information

178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21

178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21 I 178 II 180 III ( ) 181 IV 183 V 185 VI 186 178 5 I 1 ( ) ( ) 10 3 13 3 1 8891 8 3023 6317 ( 10 1914 7152 ) 16 5 1 ( ) 6 13 3 13 3 8575 3896 8 1715 779 6 (1) 2 7 4 ( 2 ) 13 11 26 12 21 14 11 21 4 10 (

More information

Our previous researches have demonstrated the enhanced angiogenesis and ectopic bone formation by a single delivery system of stromal cell-derived fac

Our previous researches have demonstrated the enhanced angiogenesis and ectopic bone formation by a single delivery system of stromal cell-derived fac Our previous researches have demonstrated the enhanced angiogenesis and ectopic bone formation by a single delivery system of stromal cell-derived factor-1 (SDF-1) and bone morphogenetic protein-2 (BMP-2)

More information

レントゲン X線

レントゲン X線 PET ( TIAN Mei ) PET 100 PET PET PET PET PET Positron Emission Tomography (PET) PET Positron Emission Tomography CT PET FDG Glucose and 18 F-FDG 18 F-FDGFDG CH3OH O CH3OH O OH OH OH OH OH OH OH 18 F *FDG

More information

-1 - -2 - -3 - -4 - -5 - -6 - -7 - -8 - -9 - - 10 - -11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - - 28 - - 29 - - 30 - - 31 - - 32

More information

untitled

untitled Y = Y () x i c C = i + c = ( x ) x π (x) π ( x ) = Y ( ){1 + ( x )}( 1 x ) Y ( )(1 + C ) ( 1 x) x π ( x) = 0 = ( x ) R R R R Y = (Y ) CS () CS ( ) = Y ( ) 0 ( Y ) dy Y ( ) A() * S( π ), S( CS) S( π ) =

More information

ron04-02/ky768450316800035946

ron04-02/ky768450316800035946 β α β α β β β α α α Bugula neritina α β β β γ γ γ γ β β γ β β β β γ β β β β β β β β! ! β β β β μ β μ β β β! β β β β β μ! μ! μ! β β α!! β γ β β β β!! β β β β β β! β! β β β!! β β β β β β β β β β β β!

More information